Compare Fabrinet (FN) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fabrinet vs Oscar Health Inc — how do they compare? Fabrinet trades at $486.28 (market cap $17.46B), while Oscar Health Inc trades at $33.37 (market cap $10.22B). The key difference: Fabrinet is the larger of the two by market cap, and Oscar Health Inc is trading nearer its 52-week high, Fabrinet nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fabrinet for 30 Days and Oscar Health Inc for 15 Days on average.
| FN | OSCR | |
|---|---|---|
Market Cap | $17.46B | $10.22B |
Volume | 1,199,886 | 4,123,394 |
Sector | Technology | Health |
52-Week High | $746.47 | $33.81 |
52-Week Low | $361.94 | $10.85 |
Typical Hold Time | 30 Days | 15 Days |
Enterprise Value | $16.59B | $6.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fabrinet (FN) trades at $487.33, down 2.14% on the day, yet maintains a bullish technical stance with strong analyst support. The stock shows robust fundamentals, with Q2 2026 EPS of $4.10 beating estimates and revenue growth accelerating to $4.6B in 2026. Positive sentiment is driven by surging AI data-center demand, though the stock faces near-term pressure from high valuations and capital expenditure concerns.
Outlook remains positive given FN's strategic position in AI infrastructure and capacity expansion, with a consensus price target of $769.50 implying significant upside. Key risks include customer concentration, margin pressure from spending, and sensitivity to tech sector volatility. The combination of strong earnings momentum and Wall Street optimism supports a constructive view for long-term investors.
OSCR trades at $33.10, up 0.58% with a bullish technical signal and strong institutional support. Recent earnings show volatility with Q1 and Q2 2026 beats but a Q4 2025 miss. Revenue grew from $11.7B in 2025 to $15.3B in 2026, with net income turning positive at $551M. Analyst consensus is mixed with 30.77% buy ratings and a $34.00 price target, slightly above current levels.
The outlook is cautiously optimistic with strong revenue growth and profitability improvements, though risks include medical cost pressures and competitive ACA market dynamics. Upside potential exists if margin expansion continues, but investors should monitor execution against guidance and healthcare sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
